Latest: FDA Approves New Biosimilar for Oncology Treatment

Addressing the Limitations of Current ITP Therapies

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like emergency steroids, shared decision-making, and interdisciplinary care to align therapy choices with each patient’s lifestyle, preferences, and comorbidities.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago